In myocardial ischaemia, vascular endothelial growth factor (VEGF) induces permeability by activating a signalling pathway that includes VEGF receptor 2 (VEGFR2), resulting in increased oedema and inflammation and thereby expanding the area of tissue damage. In this study, we investigated the role of receptor-interacting protein 2 (Rip2) in VEGF signalling and myocardial ischaemia/reperfusion injury.
Introduction
Ischaemic heart disease and myocardial infarction (MI) are among the main causes of morbidity and mortality worldwide. In ischaemic disorders, increased microvascular permeability is an early event in the deterioration of vascular integrity. Permeability is induced by vascular endothelial growth factor (VEGF), which activates a signalling pathway that includes VEGF receptor 2 (VEGFR2), Src tyrosine kinase, and extracellular signal-regulated kinase (ERK), 1,2 thereby interrupting intercellular junctions. In myocardial ischaemia, vascular permeability induced by VEGF secretion from ischaemic tissue increases oedema and inflammation and expands the area of tissue damage. 3 Consequently, developing therapeutic strategies to treat ischaemic heart disease by preserving microvascular permeability is an area of intense investigation. Myocardial damage after ischaemia and reperfusion also involves innate immune and inflammatory responses mediated by NFkB signalling. 3 -5 Inhibition of NFkB binding activity protects against myocardial ischaemic injury by inhibiting infiltration of neutrophils and monocytes to the ischaemic area. 5 In addition, NFkB activation may activate VEGF signalling and thereby induce microvascular permeability. 6 The molecular mechanisms that link inflammation and VEGF signalling are unclear. However, these mechanisms must be tightly regulated. It is plausible that single components of the NFkB signalling pathway may have intrinsic effects in regulating proteins involved in VEGF signalling, independent of NFkB activation. Receptor-interacting protein 2 (Rip2) is a serine/threonine kinase that mediates NFkB signalling. 7 -9 Its function has mainly been investigated in inflammatory cells, but Rip2 is also expressed in endothelial cells. Recently, Rip2 has been shown to play a role in regulation of lipid metabolism in macrophages, 9 and it is also known to be regulated by hypoxia. 10 Importantly, Rip2 has been unexpectedly linked to proteins such as the p75 neurotrophin receptor, 11 epidermal growth factor receptor, 12 and PPP2R1A (a scaffolding component of protein phosphatase 2A). 13 Thus, Rip2 may have functions beyond activating NFkB.
In this study, we used cultured endothelial cells as well as mice to investigate the role of Rip2 in VEGF signalling and myocardial ischaemia/ reperfusion injury. Our findings suggest a novel role for Rip2 in VEGF signalling and have implications for the treatment of myocardial ischaemia.
Methods

Cell culture experiments
Human umbilical vein endothelial cells (HUVECs) (Lonza, Walkersville, MD, USA) (passages 4 -10) were cultured in endothelial growth medium-2 (Lonza) and transfected with Silencer select siRNA targeting Rip2 or control siRNA (Ambion, Carlsbad, CA, USA); Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) was used for transfection. Twenty-four hours later, cells were incubated with endothelial basal medium-2 (Lonza) for 24 h and then stimulated with human VEGF 165 (25 or 100 ng/mL) (PeproTech, London, UK) for the indicated time. The cells were solubilized in lysis buffer containing 20 mM Tris -HCl, pH 7.4, 150 mN NaCl, 2 mM EDTA, and 1% NP-40 supplemented with protease and phosphatase inhibitor cocktails (cOmplete, Mini, EDTA-free and PhosStop; Roche Diagnostics, Mannheim, Germany). The protein concentration was measured with a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Key results have been repeated with a second Rip2-specific siRNA.
MTS assay
HUVEC viability and cell survival were assessed using the MTS CellTiter 96 w AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA), as described by the manufacturer.
Immunoprecipitation and western blot analysis of VEGF signalling
HUVEC lysates were immunoprecipitated by incubation with specific or control antibody coupled to protein G-dynabeads for 1 h at room temperature. Proteins were eluted in sample buffer by heating to 708C for 10 min. For western blot analysis, equal amounts of total protein were loaded and resolved on a NuPAGE 4 -12% Bis -Tris gel (Invitrogen) and transferred to a nitrocellulose membrane. Blots were probed with specific antibodies for VEGFR2 (#9698), pVEGFR2 (Y1175) (#2478), Erk1/2 (#9102), pErk1/2 (#9106), pAkt (S473) (#4060), Akt (#9272), Src (#2109), Rip2 (#4142) (Cell Signalling Technologies, Danvers, MA, USA), HPRT (ab109021), a-Tubulin (ab7291), VEGFR1(ab32152) (Abcam, Cambridge, MA, USA), and pSrc (Y418) (#44660G) (Invitrogen) and then with the corresponding horseradish peroxidase-conjugated secondary antibody. Immunoblots were visualized with Immobilon Western Chemiluminescent horseradish peroxidase substrate (Millipore) and a Fusion FX7 camera (Vilber Lourmat, France). Bands were quantified with FusionCapt Advance software (Vilber Lourmat) and normalized to HPRT or a-tubulin.
Mice
Rip2
2/2 mice 7 and wild-type (WT) littermates (kindly provided by Dr Paul W. Dempsey, University of California, Los Angeles, CA, USA) were housed in a pathogen-free barrier facility and fed rodent chow. All animal studies were approved by the local animal Ethics Committee and conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. At the end of experiments, mice were sacrificed using isoflurane and cervical dislocation.
2.5 mRNA expression in HUVECs and heart tissue from mice
Total RNA was extracted from HUVECs using RNeasy Mini Kit (Qiagen, Hilden, Germany) and from the snap-frozen mouse heart tissue using RNeasy Fibrous Tissue Kit (QIAGEN). cDNA was synthesized using the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems) with random primers. mRNA expression of genes of interest was analysed with TaqMan real-time polymerase chain reaction in an ABI Prism 7900 HT Detection System (Applied Biosystems). The TaqMan Gene Expression assays used were Hs01572686_m1 (for Rip2), Hs00911700_m1 (VEGFR2, KDR), Hs01052961_m1 (VEGFR1, Flt1), Mm00437304_m1 (VEGFa), and Mm01222421_m1 (VEGFR2, kdr), and Hs02800695_m1 or Mm01545399_m1 (HPRT) was used as internal control (all from Applied Biosystems).
Induction of myocardial ischaemia/ reperfusion and infarction
For sedation and breathing support during the operation, the mice were anaesthetized with isoflurane, orally intubated, and connected to a respirator (SAR-830 small animal ventilator, GENEQ, Montreal, Canada), distributing a mixture of oxygen, air, and 2 -3% isoflurane. Cardiac rhythm was monitored with electrodes placed on the extremities and connected to an ECG monitor. An incision was made between the fourth and fifth ribs to expose the upper part of the anterior left ventricular (LV) wall and the lower part of the left atrium. Myocardial ischaemia/reperfusion was induced by a temporary ligation of left anterior descending (LAD) coronary artery. A suture was passed below the proximal segment of the LAD coronary artery just distal to the left atrial appendage. Both ends of the suture were passed through a short piece of narrow polyethylene tube and pulled gently to exert enough pressure to temporarily occlude the LAD. Coronary occlusion was verified by ECG and visual inspection by observing colour changes of the tissue. After 45 min, the ligation was released, and reperfusion was verified by the return of the heart to normal colour. The mice were subject to 24 h reperfusion. MI was induced by ligating the LAD coronary artery immediately distal to the bifurcation of the left coronary artery. The efficacy of the procedure was immediately verified by characteristic ECG changes and akinesis of the LV anterior wall. After verification of infarction, the lungs were hyperinflated, positive end-expiratory pressure was applied, and the chest was closed. The mice received Temgesic (0.1 mL i.p.) to relieve post-operative pain and recovered spontaneously when the isoflurane was turned off.
Measurements of area at risk and infarct area
Three hours after occlusion, the mice were sedated and coupled to a ventilator. The chest was opened and the right ventricle was injected with Evans Blue dye, which coloured all perfused tissue and left the ischaemic zone (area at risk, AAA) uncoloured. The heart was excised, rinsed in saline, frozen at 208C, and cut into 1 mm slices. The slices were incubated in triphenyltetrazolium (1%) solution at 378C for 15 min. Tetrazolium stains the surviving tissue red; the infarcted tissue has a pale white/yellowish colour. Infarct size was calculated as a percentage of the area at risk.
Echocardiography
Mice were anaesthetized with isoflurane (1.2%) and underwent a baseline echocardiographic examination with a VisualSonics VEVO 770 system (VisualSonics, Ontario, Canada), which includes an integrated rail system for consistent positioning of the ultrasound probe. The chests were shaved, and hair removal gel was applied to minimize resistance to ultrasonic beam transmission. The mice were then placed on a heating pad, and their paws were connected to an ECG. A 45 MHz linear transducer (RMV 704) was used for imaging. An optimal parasternal long-axis cine loop (which shows both the mitral and aortic valves and the maximum distance between the aortic valve and the cardiac apex) was acquired at .1000 frames/s with the ECG-gated kilohertz visualization technique. Parasternal short-axis cine loops were acquired at 1, 3, and 5 mm below the mitral annulus.
End-diastolic and end-systolic LV volumes and ejection fraction were calculated with Simpson's biplane formula using the three parasternal short-axis views and the parasternal long-axis view. M-mode measurements were made (at the 3 mm level) with the leading-edge method. End-diastole was defined as the onset of the QRS complex; end-systole was defined as the time of peak inward motion of the interventricular septum. At least three beats were averaged for each measurement. LV fractional shortening was calculated as (LVIDd2LVIDs)/LVIDd × 100, where LVIDd and LVIDs are the LV internal diameters in diastole and systole, respectively. Each echocardiographic examination was performed by an experienced echocardiographer.
The data were stored offline and evaluated in a blinded fashion with VevoStrain software system (VisualSonics).
Modified Miles assay
Modified Miles assay was performed as described previously by Galaup et al. 14 In short, for measurement of vascular permeability before and after MI, male mice (n ¼ 8 for WT baseline, 12 for WT MI, and 7 for Rip2 2/2 MI) were used. Twenty-four hours after MI, the mice were anaesthetized with isoflurane and 1% Evans Blue (200 mL) was administered intravenously by retro-orbital injection. After 4 h, the mice were euthanized and the hearts were perfused with citrate buffer, pH 4. The ventricular septum wall was dissected, and Evans Blue was extracted from heart tissue in 1 mL of formamide for 18 h at 708C. The absorbance was measured at 620 nm, and the amount of Evans Blue (mg) was determined from a standard curve and normalized to tissue weight (g). For baseline vascular permeability measurement in the ventricles, female Rip2 2/ 2 mice (n ¼ 7) and wild-type littermates (n ¼ 4) were used and Evans Blue was administrated as described earlier and after perfusion the ventricles were dissected out and Evans Blue was extracted and measured, as described earlier.
Immunohistochemistry
Rip2 2/2 and WT hearts were embedded in OCT Cryomount (Histolab Products AB, Gö teborg, Sweden), frozen in liquid nitrogen-cooled isopentane, and cut into 10 mm thick cross-sections. Heart tissue sections were fixed in 2% formaldehyde for 5 min, washed three times in phosphatebuffered saline (PBS), permeabilized in 0.1% Triton X-100 in PBS for 2 min, washed three times in PBS, and blocked in 1% bovine serum albumin in PBS for 20 min. After blocking endogenous biotin in the sections using an avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA, USA), the sections were incubated with anti-CD18 antibody (Cerdarlane Laboratories Limited, Hornby, Ontario, Canada) for 2 h and then with biotinylated rabbit anti-rat IgG (Vector Laboratories) for 30 min and exposed to Vectastain ABC-AP kit (Vector Laboratories) for 30 min and developed with Warp Red Chromogen kit (Biocare Medical, Concord, CA, USA) for 12 min. Sections were counterstained with Mayers HTX. Heart sections were also stained for haematoxylin and eosin (HE). Oedema was quantified on HE-stained sections from hearts with ischaemia -reperfusion of both genotypes, according to Galaup et al.
14 High-resolution images covering the entire heart areas were obtained using a Mirax digital slide scanner (Carl Zeiss, Germany).
Statistical analysis
Data are shown as means + SEM. Comparisons between two groups were made using paired or unpaired two-tailed t-test. Comparisons between more than two groups were made by one-way analysis of variance followed by Dunnett's multiple comparisons test (alpha 0.05). P , 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism Software.
Results
Altered VEGFR2 kinetics in cultured endothelial cells with silenced Rip2
To investigate whether Rip2 participates in VEGF signalling, we used cultured endothelial cells in which Rip2 was or was not silenced with Rip2 siRNA. Treatment with Rip2 siRNA almost entirely abolished expression of Rip2 mRNA and protein ( Figure 1A and Supplementary material online, Figure S1 ). Cell proliferation and viability were not affected by silencing Rip2 (Supplementary material online, Figure S2 ). VEGF stimulation resulted in phosphorylation of VEGFR2 at tyrosine 1175, and the kinetics of phosphorylation differed in the two types of cells ( Figure 1A) . In control cells, VEGFR2 phosphorylation peaked at 5 min and remained increased for 15 min. However, in cells treated with Rip2 siRNA, VEGFR2 phosphorylation peaked at 1 min and then declined rapidly ( Figure 1B) , suggesting more rapid kinetics for VEGFR2 signalling. In addition, phosphorylation of Y951 and Y1214 was also markedly lower in cells treated with Rip2 siRNA ( Figure 1C -F) . VEGF-induced activation of Src trended lower in endothelial cells treated with Rip2 siRNA ( Figure 1A and B) , but not to the same extent as for pVEGFR2. Our findings indicate that Rip2 regulates VEGFR2 phosphorylation directly or indirectly. To investigate whether there is a direct physical interaction between Rip2 and VEGFR2, we performed immunoprecipitation experiments to evaluate a possible binding of VEGFR2 to Rip2. However, we did not identify VEGFR2 after immunoprecipitation of Rip2 (Supplementary material online, Figure  S3 ), suggesting that Rip2 regulates VEGFR2 signalling indirectly. Collectively, our results show that Rip2 modifies VEGF signalling. Silencing Rip2 in endothelial cells results in more rapid kinetics of VEGFR2 signalling, suggesting an increased turnover of VEGFR2.
Enhanced susceptibility to endothelial permeability in cultured endothelial cells with silenced Rip2
Because downstream VEGFR2 signalling regulates endothelial junction stability and microvascular permeability, we assessed activation states of ERK1/2 and Akt in cultured endothelial cells. As expected, VEGF transiently activated ERK1/2 and Akt. Strikingly, 10 min after VEGF stimulation, activation of ERK1/2 was two-fold higher in Rip2 siRNA cells than that in control cells (Figure 2A and B) . The activation of Akt peaked earlier in Rip2 siRNA cells than in control cells; however, this was not statistically significant ( Figure 2A and C) . The mRNA levels of VEGFR1 and VEGFR2 were significantly increased by Rip2 silencing, but the protein levels did not differ between cells with or without Rip2 (Supplementary material online, Figure S4 ). Our findings thus suggest that increased turnover of VEGFR2 in cultured endothelial cells leads to enhanced VEGF-induced activation of ERK1/2, indicating increased susceptibility to endothelial permeability in Rip2 siRNA endothelial cells.
Myocardial ischaemia and reperfusion
induce vascular permeability and pronounced oedema in Rip2 2/2 mice Next, we investigated whether Rip2 has a role in microvascular permeability in the heart. To analyse the baseline vascular permeability in WT and Rip2 2/2 hearts, we performed a Miles assay and assessed leakage of Evans Blue dye. There was a trend towards increased vascular leakage in Rip2 2/2 hearts, but there was no statistical difference (Supplementary material online, Figure S5 ). mRNA levels of VEGF and VEGFR2 were not different between WT and Rip2 2/2 mice (Supplementary material online, Figure S6 ). We then assessed vascular permeability in hearts of WT and Rip2 2/2 mice after induced myocardial ischaemia.
As expected, we found that myocardial permeability was increased following ischaemia ( Figure 3A) . In addition, ischaemia-induced permeability was markedly higher in Rip2 2/2 hearts than in WT hearts ( Figure 3A ), in agreement with our findings from in vitro studies. Next, to assess oedema after 45 min of ischaemia and 24 h of reperfusion, we analysed HE-stained sections from hearts of both genotypes. Indeed, oedema was more pronounced in Rip2 2/2 than in WT mice after myocardial ischaemia/reperfusion ( Figure 3B and C ). No haemorrhage was detected in the hearts (data not shown).
Myocardial ischaemia and reperfusion increase LV mass and relative wall thickness in Rip2 2/2 mice
Because increased microvascular permeability and oedema occur early in ischaemic disorders, we determined the effects on heart morphology, dimension, and function. Baseline LV function was actually better in Rip2 2 /2 mice than in WT mice, but there were no differences in baseline LV dimensions ( Table 1) . We then induced myocardial ischaemia and reperfusion in WT and Rip2 2/2 mice and assessed heart dimensions and function by echocardiography. Importantly, Rip2 2/2 mice had a higher relative LV wall thickness ( Figure 4A ) and LV mass ( Figure 4B ) due to a thickening of the anterior wall in diastole ( Figure 4C ) 24 h after ischaemia/reperfusion, likely as an effect of the increased oedema found in Rip2 2/2 hearts. Posterior wall dimensions were not altered ( Figure 4D) . The area at risk did not differ between the groups, but the infarct area was significantly increased in Rip2 2/ 2 hearts ( Figure 4E and F ) . In addition, Rip2 deficiency had no effect on heart function 24 h after ischaemia/reperfusion (data not shown). Furthermore, infiltration of leucocytes in the area of myocardial damage was greater in Rip2 2/ 2 hearts than in WT hearts ( Figure 4G and H ) , indicating an expanding area of tissue damage in Rip2 2/2 hearts.
Thus, Rip2 deficiency increases microvascular permeability, oedema, and thickening of the anterior LV wall following ischaemia. These findings are consistent with a role for Rip2 in myocardial ischaemia/reperfusion injury.
Reduced heart function in Rip2
2/2 mice after MI
To evaluate the long-term effects of microvascular dysfunction in Rip2 2/2 mice, we induced MI by permanently occluding the LAD coronary artery in WT and Rip2 2/2 mice. One month later, both average LV wall thickness and LV posterior wall thickness ( Figure 5A ) were lower in Rip2 2/2 mice, consistent with altered remodelling after infarction.
Further, LV volumes trended higher in Rip2 2/2 mice ( Figure 5B ). There was no difference in fibrotic areas or in vascular density in the hearts (data not shown). However, heart function was markedly lower in Rip2 2/2 mice than in WT mice, as assessed by measuring ejection fraction ( Figure 5C ) and the change in fractional area ( Figure 5D ). Evidently, microvascular dysfunction enhances myocardial damage and markedly reduces heart function following myocardial ischaemia in Rip2 2/2 mice.
Discussion
In this study, we investigated the role of Rip2 in VEGF signalling and vascular stability in the setting of myocardial ischaemia/reperfusion injury. Notably, we found that Rip2 deficiency in endothelial cells altered VEGFR2 kinetics and enhanced VEGF-induced expression of pERK. In a model of myocardial ischaemia, we found that Rip2 2 /2 mice have increased microvascular permeability in the heart compared with WT mice. In addition, Rip2 2/2 mice have thickening of the LV anterior wall as a result of severe oedema and increased areas of myocardial damage, and Rip2 2 /2 mice also display markedly reduced heart function after long-term follow-up. These findings indicate that Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia. Following myocardial ischaemia, VEGF expression is induced in response to hypoxia, leading to angiogenesis that will improve tissue healing. 15 However, VEGF signalling will also lead to vascular permeability and oedema, causing widespread myocardial injury. 14, 16 Early reperfusion after ischaemia is essential for maintaining cardiac integrity and function. However, reperfusion in itself causes vascular injury leading to interstitial oedema, which further increases myocardial damage. Protection of cardiac tissue from ischaemia/reperfusion injury is therefore an essential aspect of treatment for MI. Indeed, despite its promise in promoting angiogenesis, some attempts to use VEGF gene therapy to treat ischaemic heart disease have resulted in immature and leaky vessels. 17, 18 However, other attempts have been more successful. For example, promoting expression of VEGF-B has proven to be advantageous in reducing myocardial damage following ischaemia. 19 Generation of chimeras between VEGF and angiopoietin has also shown sustained angiogenesis, but reduced vessel permeability. 20 In addition, angiotensin-1 had beneficial effects in the treatment of ischaemia/reperfusion, 21 and Frizzled7 has shown promising results in initial studies. 22 Our findings show that Rip2 modifies VEGF signalling. In Rip2 2/2 endothelial cells, stimulation with VEGF resulted in the phosphorylation of VEGFR2 and altered the kinetics of phosphorylation, which peaked earlier and declined faster than that in WT cells. These results suggest faster induction of tyrosine phosphorylation and increased turnover of VEGFR2. The dynamics of VEGFR2 trafficking influences its downstream signalling activities. 23 ERK and Akt signalling can be initiated from endosomal compartments, 24 suggesting that the increased turnover of VEGFR2 leads to the enhanced downstream signalling seen in endothelial cells with silenced Rip2. The molecular mechanism by which Rip2 regulates VEGF signalling is unclear. There are several conceivable models. Rip2 may function as a scaffolding protein for VEGFR2; Rip2 may directly bind to VEGFR2, and Rip2 inactivation may lead to altered kinetics of VEGFR2 and enhanced downstream signalling. However, we could not identify a direct binding between Rip2 and VEGFR2. It is therefore plausible that the interaction between Rip2 and VEGFR2 is indirect, possibly through interaction between Rip2 and a co-factor of VEGFR2. Several links between Rip2 signalling and VEGF signalling have been established. For example, spleen tyrosine kinase, a downstream signalling protein of Rip2, 9, 25 has been linked to VEGFR2. 26 Vav/rac signalling has also been linked to Rip2 signalling 27,28 and VEGFR2 activation. VEGF signalling is central both in the formation of new blood vessels and in the regulation of permeability in existing vessels. 30 VEGFR2
2/2 mice, with no VEGFR2 signalling, cannot form blood vessels and die early in embryogenesis. 31 Altered VEGF signalling in Rip2 2/2 mice is associated with increased vascular permeability but without any vascular abnormalities or any chronic effects on angiogenesis, suggesting that the altered VEGF signalling seen in Rip2 2/2 mice may be important in pathological conditions in which vascular permeability may increase, such as ischaemic heart disease or tumour development. Our data indicate that the increased vascular permeability in Rip2 2/2 hearts is caused by enhanced VEGF signalling in endothelial cells. However, we cannot exclude that other mechanisms, established as a consequence of Rip2 deletion, affect vascular permeability and myocardial function.
Recently, attention has been focused on inhibition of Rip2 as a pharmaceutical target. 32 Indeed, Rip2 activity has been implicated in inflammatory diseases such as asthma, inflammatory arthritis, and multiple sclerosis, suggesting inhibition of this signalling pathway as a novel pharmaceutical target in inflammatory disease. Small-molecule tyrosine kinase inhibitors of Rip2 have been successful in the treatment of inflammatory disease in mice. 33 Pharmaceutical studies of these compounds suggest that inhibition of Rip2 kinase normalizes proinflammatory output signalling and that Rip2 may be a viable pharmacological target to modulate inflammatory disease. However, our findings suggest that such treatment may have unexpected off-target effects, such as induction of microvascular permeability and oedema. Therefore, possible off-target effects must be evaluated before using these inhibitors to treat human subjects.
In conclusion, this study provides evidence that Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia. Therefore, Rip2 may be a promising novel therapeutic approach to reduce excess vascular permeability in ischaemic heart disease.
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